11.92
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
What drives Ocular Therapeutix Inc. stock priceMassive wealth growth - Autocar Professional
Ocular Therapeutix stock hits 52-week high at $11.78 - Investing.com India
What analysts say about Ocular Therapeutix Inc. stockAccelerated wealth building - Autocar Professional
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
Ocular Therapeutix Inc. Stock Analysis and ForecastRecord-breaking gains - jammulinksnews.com
Ocular Therapeutix Announces Participation in Upcoming Scientific Conferences Focused on Retina Innovation - Quiver Quantitative
Ocular Therapeutix Participates in Upcoming Scientific Conferences - AInvest
Ocular Therapeutix Unveils Breakthrough Diabetic Retinopathy Treatment Data Across 3 Major Eye Conferences - Stock Titan
Is Ocular Therapeutix Inc. a good long term investmentRemarkably fast returns - jammulinksnews.com
(OCUL) Trading Report - news.stocktradersdaily.com
FMR LLC's Strategic Acquisition of Ocular Therapeutix Shares: A Financial Analysis - AInvest
Ocular Therapeutix(OCUL) Soars 8.47% on Pipeline Progress - AInvest
Institutional investors control 65% of Ocular Therapeutix, Inc. (NASDAQ:OCUL) and were rewarded last week after stock increased 3.7% - simplywall.st
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) dropped from Russell 3000E Index - MarketScreener
Ocular Therapeutix, Inc.(NasdaqGM: OCUL) dropped from Russell 3000E Growth Index - MarketScreener
Selling US$1.1m Of Ocular Therapeutix Stock Rewarded Insiders - 富途牛牛
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - The Manila Times
Ocular Therapeutix Launches New Corporate Branding to Enhance Retina-Focused Mission - Nasdaq
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Yahoo Finance
Pre-market Movers: NKTR, INM, IBIO, IBO... - RTTNews
OCUL SEC FilingsOcular Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Trend Tracker for (OCUL) - news.stocktradersdaily.com
Ocular Therapeutix to present at Clinical Trials at the Summit 2025 - Ophthalmology Times
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years - Yahoo Finance
Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade) (OCUL) - Seeking Alpha
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 | OCUL Stock News - GuruFocus
Ocular Therapeutix, Inc. to Present Clinical Trial Results and Insights at Summit 2025 in Las Vegas - Nasdaq
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewswire
Breakthrough Eye Disease Treatment Data: Ocular Therapeutix Reveals Clinical Trial Results at CTS 2025 - Stock Titan
Ocular Therapeutix Approves Key Amendments at Annual Meeting - TipRanks
Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology - insights.citeline.com
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors - simplywall.st
Trading (OCUL) With Integrated Risk Controls - news.stocktradersdaily.com
Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
What is HC Wainwright’s Forecast for OCUL Q1 Earnings? - Defense World
Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN
Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright - Defense World
Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus
Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga
Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):